A comparative in vitro study of percutaneous penetration of β-blockers in human skin

International Journal of Pharmaceutics

Volumn 194, Issue 2, 2000, Pages 249-259

  Modamio, P ^a   Lastra, C F ^a   Marino E L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Atenolol; Human skin; In vitro; Metoprolol; Oxprenolol; Percutaneous permeation; Propranolol

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CELIPROLOL; DRUG VEHICLE; METOPROLOL; OXPRENOLOL; PROPRANOLOL;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DIFFUSION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN TISSUE; LIPOPHILICITY; PRIORITY JOURNAL; SKIN PENETRATION;

ADMINISTRATION, CUTANEOUS; ADRENERGIC BETA-ANTAGONISTS; FEMALE; HUMANS; PERMEABILITY; SKIN; SOLUBILITY; TEMPERATURE;

EID: 0033955626     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00380-4     Document Type: Article

References (53)

1. Ademola J.I., Chow C.A., Wester R.C., Maibach H.I. Metabolism of propranolol during percutaneous absorption in human skin. J. Pharm. Sci. 82:1993;767-770.
2. Ahmed S., Imai T., Otagiri M. Stereoselectivity in cutaneous hydrolysis and transdermal transport of propranolol prodrugs. Pharm. Res. 2:1997;181-191.
3. Barbato F., Caliendo G., La Rotonda M.I., Morrica P., Silipo C., Vittoria A. Relationships between octanol-water partition data, chromatographic indices and their dependence on pH in a set of beta-adrenoceptor blocking agents. Il Farmaco. 45:1990;647-663.
4. Betageri G.W., Rogers J.A. Thermodynamics of partitioning of β-blockers in the n-octanol buffer and liposome systems. Int. J. Pharm. 36:1987;165-173.
5. Burgot G., Serrand P., Burgot J.L. Thermodynamics of partitioning in the n-octanol/water systems of some β-blockers. Int. J. Pharm. 63:1990;73-76.
6. British Pharmacopoeia, 1998. The Stationery Office, London, vol. I, pp. 122, 123, 889-891, 971, 972, 1103, 1104.
7. Brouwers J.R.B.J. Advanced and controlled drug delivery systems in clinical disease management. Pharm. World Sci. 18:1996;153-162.
8. Caplar V., Mikotic-Mihun Z., Hofman H., Kuftinec J., Kajfez F., Nagl A. et al. Atenolol. Florey K. Analytical Profiles of Drug Substances. 13:1984;1-25 Academic Press, San Diego, CA.
9. Clarke F.H. Ionization constants by curve fitting: application to the determination of partition coefficients. J. Pharm. Sci. 73:1984;226-230.
10. Clarke, F.H., 1986. In: Clarke, E.G.C., Moffat, A.C., Thomas, W.G., Wade, A. (Eds.), Clarke's Isolation and Identification of Drugs, 2nd edition. The Pharmaceutical Press, London, pp. 780-779, 839, 936-938.
11. Clarke F.H., Cahoon N.M. Ionization constants by curve fitting: determination of partition and distribution coefficients of acids and bases and their ions. J. Pharm. Sci. 76:1987;611-620.
12. Corbo M., Liu J.C., Chien Y.W. Bioavailability of propranolol following oral and transdermal administration in rabbits. J. Pharm. Sci. 79:1990;584-587.
13. Demou J.S., Sidhom M.B., Plakogiannis F.M. Comparative in vitro diffusion studies for atenolol transdermal delivery systems. Pharm. Acta Helv. 68:1994;215-219.
14. Flynn G.L. Physicochemical determinants of skin absorption. Gerrity T.R., Henry C.J. Principles of Route-to-Route Extrapolation for Risk Assessment. 1990;93-127 Elsevier, New York, NY.
15. Franz T.J. Percutaneous absorption. On the relevance of in vitro data. J. Invest. Dermatol. 64:1975;190-195.
16. Ghosh T.K., Habib M.J., Childs K., Alexander M. Transdermal delivery of metoprolol I: comparison between hairless mouse and human cadaver skin and effect of n-decylmethyl sulfoxide. Int. J. Pharm. 88:1992;391-396.
17. Ghosh T.K., Chiao C.S., Gokhale R. In vitro release and permeation of levobunolol from various transdermal formulations. Int. J. Pharm. 82:1992;39-45.
18. Ghosh T.K., Chiao C.S., Gokhale R.D. In-vitro permeation of some β-blockers across the hairless mouse skin. J. Pharm. Pharmacol. 45:1993;218-219.
19. Ghosh T.K., Adir J., Xiang S.L., Onyilofur S. Transdermal delivery of metoprolol II: in-vitro skin permeation and bioavailability in hairless rats. J. Pharm. Sci. 84:1995;158-160.
20. González A.G., Herrador M.A., Asuero A.G. Hydrophobicity of β-adrenoceptor blocking agents: study of correlations between retention in reversed-phase HPLC systems and octanol-water partition constants. Int. J. Pharm. 120:1995;215-220.
21. Green P.G., Hadgraft J. Facilitated transfer of cationic drugs across a lipoidal membrane by oleic acid and lauric acid. Int. J. Pharm. 37:1987;251-255.
22. Heard C.M., Watkinson A.C., Brain K.R., Hadgraft J. In vitro skin penetration of propranolol enantiomers. Int. J. Pharm. 90:1993;R5-R8.
23. Hirvonen J., Kontturi K., Murtomäki L., Paronen P., Urtti A. Transdermal iontophoresis of sotalol and salicylate; the effect of skin charge and penetration enhancers. J. Control. Release. 26:1993;109-117.
24. Hori M., Satoh S., Maibach H.I., Guy R.H. Enhancement of propranolol hydrochloride and diazepam skin absorption in vitro: effect of enhancer lipophilicity. J. Pharm. Sci. 80:1991;32-35.
25. Karzel K., Liedtke R.K. Mechanismen transkutaner resorption, pharmalologische und biochemische aspekte. Arzneim.-Forsch./Drug Res. 39:1989;1487-1491.
26. Kemken J., Ziegler A., Müller B.W. Investigations into the pharmacodynamic effects of dermally administered microemulsions containing β-blockers. J. Pharm. Pharmacol. 43:1991;679-684.
27. Kobayashi I., Hosaka K., Ueno T., Maruo H., Kamiyama M., Konno C., Gemba M. Relationship between amount of beta-blockers permeating through the stratum corneum and skin irritation after application of beta-blockers adhesive patches to guinea pig skin. Biol. Pharm. Bull. 20:1997;421-427.
28. Krishna R., Pandit J.K. Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J. Pharm. Pharmacol. 48:1996;367-370.
29. Ktistis G., Niopas I. A study on the in-vitro percutaneous absorption of propranolol from disperse systems. J. Pharm. Pharmacol. 50:1998;413-418.
30. Kunta J.R., Goskonda V.R., Brotherton H.O., Khan M.A., Reddy I.K. Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. J. Pharm. Sci. 86:1997;1369-1373.
31. Le Brun P.P.H., Fox P.L.A., de Vries M.E., Boddé H.E. In vitro penetration of some β-adrenoceptor blocking drugs through porcine buccal mucosa. Int. J. Pharm. 49:1989;141-145.
32. Luch J.R. Metoprolol tartrate. Florey K. Analytical Profiles of Drug Substances. 12:1983;325-356 Academic Press, San Diego, CA.
33. Martindale, The Extra Pharmacopoeia, 1996, In: Reynolds, J.E.F. (Ed.), The Royal Pharmaceutical Society of Great Britain, London, 31st edition, pp. 827, 908, 925, 936.
34. Melendres J.L., Nangia A., Sedik L., Hori M., Maibach H.I. Nonane enhancers propranolol hydrochloride penetration in human skin. Int. J. Pharm. 92:1993;243-248.
35. Mey C., Enterling D., Ederhof M., Wesche H., Osterwald H. Transdermal delivery of mepindolol and propranolol in normal man. 1st communication: study design, clinical and pharmacodynamic aspects. Arzneim-Forsch./Drug Res. 39:1989;1505-1508.
36. Modamio P., Montejo O., Lastra C.F., Mariño E.L. A valid high-performance liquid chromatography method for oxprenolol stability studies. Int. J. Pharm. 112:1994;93-96.
37. Modamio P., Montejo O., Lastra C.F., Mariño E.L. Development and validation of liquid chromatography methods for the quantitation of propranolol, metoprolol, atenolol and bisoprolol: application in solution stability studies. Int. J. Pharm. 130:1996;137-140.
38. Modamio P., Lastra C.F., Mariño E.L. Transdermal absorption of celiprolol and bisoprolol in human skin in vitro. Int. J. Pharm. 173:1998;141-148.
39. Ogiso T., Ito Y., Iwaki M., Shintani A. The percutaneuos absorption of propranolol and prediction of the plasma concentration. J. Pharmacobio.-Dyn. 11:1988;349-355.
40. Okamoto H., Komatsu H., Hashida M., Sezaki H. Effects of β-cyclodextrin and di-o-methyl-β-cyclodextrin on the percutaneuos absorption of butylparaben, indomethacin and sulfanilic acid. Int. J. Pharm. 30:1986;35-45.
41. Potts R.O., Guy R.H. Predicting skin permeability. Pharm. Res. 9:1992;663-669.
42. Riddell J.G., Harron D.W.G., Shanks R.G. Clinical pharmacokinetics of β-adrenoceptor antagonists. Clin. Pharmacokinet. 12:1987;305-320.
43. Sasaki H., Igarashi Y., Nishida K., Nakamura J. Intestinal permeability of ophthalmic β-blockers for predicting ocular permeability. J. Pharm. Sci. 83:1994;1335-1338.
44. Schoenwald R.D., Huang H.-S. Corneal penetration behaviour of β-blocking agents I: physicochemical factors. J. Pharm. Sci. 112:1983;1266-1271.
45. Spieker C., Vetter W., Zidek W., Vetter H. Evaluation of the therapeutic effect of transdermal β-blocker therapy in patients with essential hypertension. Arzneim-Forsch./Drug Res. 39:1989;1512-1514.
46. The Merck Index, 1996. In: Budavari, S. (Ed.), Merck, Rahway, NJ, 12th edition, pp. 145, 1050, 1347, 1348.
47. Touitou E., Chow D.D., Lawter J.R. Chiral β-blockers for transdermal delivery. Int. J. Pharm. 104:1994;19-28.
48. USP XXIII, 1995. The United States Pharmacopeial Convention, Rockville, MD, pp. 1015, 1124, 1327.
49. Vanbever R., Lecouturier N., Preat V. Transdermal delivery of metoprolol by electroporation. Pharm. Res. 11:1994;1657-1662.
50. Wang W., Sasaki H., Chien D.S., Lee V.H. Lipophilicity influence on conjuntival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res. 10:1991;571-579.
51. Williams A.C., Cornwell P.A., Barry B.W. On the non-Gaussian distribution of human skin permeabilities. Int. J. Pharm. 86:1992;69-77.
52. Yalkowsky S.H., Valvani S.C. Solubility and partitioning I: solubility of nonelectrolytes in water. J. Pharm. Sci. 69:1980;912-922.
53. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T.A. Pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharm. Dyn. 6:1981;165-176.